10-Q: Enzo Biochem Reports Q3 Loss Amid Revenue Decline and Strategic Review, Delists from NYSE

Enzo Biochem, a life sciences company, reported a wider quarterly operating loss and a significant revenue decline for the three months ended April 30, 2025, while announcing a strategic review and its voluntary delisting from the NYSE to OTCQX.

Summary

• Enzo Biochem reported a net loss of $2.79 million for the three months ended April 30, 2025, an improvement from $3.02 million in the prior year period.
• Revenues from continuing operations (Products segment) decreased by 20% to $6.4 million for the three months ended April 30, 2025, compared to $8.0 million in the same period last year, primarily due to headwinds in the life sciences tools sector.
• For the nine months ended April 30, 2025, revenues from continuing operations were $19.9 million, down 18% from $24.4 million in the prior year.
• The company's gross profit margin from continuing operations declined to 39% (41% excluding inventory provision) for the three months ended April 30, 2025, from 47% in the prior year, impacted by reduced revenues and fixed manufacturing costs.
• Operating loss from continuing operations widened to $3.389 million for the three months ended April 30, 2025, from $2.043 million in the prior year.
• Net loss from discontinued operations (Enzo Clinical Labs) improved significantly, from $0.889 million to $0.416 million for the three months, and from $4.028 million to $1.008 million for the nine months ended April 30, 2025.
• Cash and cash equivalents decreased by $15.7 million, from $52.4 million at July 31, 2024, to $36.7 million at April 30, 2025, primarily due to net loss, accrued liability payments, and a $5.3 million cash dividend.
• The company's Board of Directors initiated a review of strategic alternatives on April 22, 2025, including a potential transaction, business combination, full sale, or return of excess capital to shareholders.
• Enzo Biochem voluntarily delisted its common stock from the NYSE on April 17, 2025, and began trading on OTCQX under the symbol ENZB on April 21, 2025, following non-compliance with NYSE listing standards.
• A $5.0 million escrowed fund from the Labcorp Asset Purchase Agreement was released to the company on October 30, 2024.
• The company reached a class-wide settlement of $7.5 million for the April 2023 data breach litigation, with approximately $0.8 million paid in March 2025 and the remaining $6.7 million due by July 10, 2025.
• Settlements totaling $4.5 million related to regulatory inquiries from the New York, Connecticut, and New Jersey Attorneys General regarding the ransomware attack were paid in September 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant revenue decline in the core business, deteriorating gross margins, widening quarterly operating losses, and the voluntary delisting from NYSE. While there are improvements in overall net loss and reduced legal expenses from past matters, the fundamental business performance is weak. The strategic review offers potential upside but is uncertain.

Positives

• The company's net loss improved to $2.79 million for the three months ended April 30, 2025, from $3.02 million in the prior year, and to $7.701 million for the nine months, from $12.697 million.
• Net loss from discontinued operations significantly improved, reflecting the successful exit from the clinical services business.
• The Board initiated a strategic review process, engaging BroadOak Capital Partners, which could lead to value maximization for shareholders.
• A $5.0 million escrowed fund from the Labcorp Asset Purchase Agreement was released to the company, boosting cash flow from investing activities.
• Legal and related expenses decreased by 33% ($0.2 million) for the three months and 50% ($1.3 million) for the nine months ended April 30, 2025, compared to the prior year, indicating reduced corporate legal matters.
• Research and development expenses decreased by 17% ($0.1 million) for the three months and 24% ($0.5 million) for the nine months, reflecting cost containment measures.
• The company experienced a favorable foreign exchange gain of $0.5 million for the three months and $0.1 million for the nine months, compared to losses in the prior year periods, due to appreciation of British pound and Swiss franc against the U.S. dollar.

Negatives

• Revenues from continuing operations (Products segment) significantly decreased by 20% to $6.4 million for the three months and 18% to $19.9 million for the nine months ended April 30, 2025, due to industry headwinds.
• Gross profit margin from continuing operations declined to 39% (41% excluding inventory provision) for the three months and 43% (45% excluding inventory provision) for the nine months, from 47% in both prior year periods.
• Operating loss from continuing operations widened by 66% to $3.389 million for the three months ended April 30, 2025.
• Cash and cash equivalents decreased by $15.7 million from July 31, 2024, to April 30, 2025, indicating continued cash burn from operations and dividend payments.
• The company voluntarily delisted from the NYSE to OTCQX due to non-compliance with listing standards, which may negatively impact liquidity and investor perception.
• The company incurred a $0.2 million inventory provision for the three months and $0.4 million for the nine months ended April 30, 2025, for inventory intended for manufacturing and sale to laboratory customers, indicating potential issues with inventory management or demand.
• Interest income decreased by 47% for the three months and 44% for the nine months, due to lower cash balances and declining interest rates.

Risks

• Continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, tariffs uncertainty, and timing of large orders fulfillment, could further impact revenue.
• The strategic review process may not result in any transaction or other strategic outcome, potentially failing to maximize shareholder value.
• Ongoing litigation related to the April 2023 ransomware attack, including an unresolved inquiry from the U.S. Department of Health and Human Services Office for Civil Rights and pending state class actions, could lead to additional liabilities.
• The whistleblower complaint alleging false billing of Medicaid and Medicare for COVID-19 tests, if successful, could result in significant financial penalties.
• The arbitration with former CEO Elazar Rabbani, scheduled for November 2025, could result in additional financial obligations for the company.
• The appraisal action initiated by James G. Wolf et al. seeking a higher valuation for their shares could result in a significant payout if their contention of fair value greater than $3.50 per share is upheld.
• The final rejection of patent claims in the ex parte reexamination proceedings for the '197 patent could weaken the company's intellectual property position and ongoing patent infringement litigation against Becton Dickinson.
• The company's reliance on estimates and assumptions in financial reporting, particularly for contingencies, inventory, and income taxes, means actual results could differ materially.
• The voluntary delisting from NYSE to OTCQX may reduce the company's visibility, liquidity, and access to capital markets.

Future Outlook

The company's management believes it has sufficient funds to meet its operating requirements for at least the next twelve months. The Board has initiated a strategic review process to evaluate opportunities to maximize shareholder value, including potential strategic transactions, business combinations, a full sale of the company, or a return of excess capital to shareholders. However, there is no assurance that this process will result in any transaction or specific strategic outcome. The company is also evaluating the impact of new accounting pronouncements (ASU 2023-09, ASU 2023-07, ASU 2024-03) on its future financial statements and disclosures.

Management Comments

• "The decline in the 2025 period gross profit was driven by the reduction in revenues, which did not fully cover overhead burden and other fixed manufacturing costs."
• "At the end of the 2025 period as compared to its start, the British pound and Swiss franc greatly appreciated compared to the U.S. dollar as a result of U.S. economic policies, which resulted in revaluation gains on certain assets and liabilities carried in those foreign currencies."
• "Based on the current available working capital, management believes the Company has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report."
• "There can be no assurance that the Company’s strategic review process will result in any transaction or other strategic outcome. The Company does not intend to disclose further developments on this strategic review process unless and until a transaction is approved and entered into, or the process is discontinued."
• "We believe there are meritorious defenses to the claims set forth in the [whistleblower] complaint and the Company will vigorously defend itself."

Industry Context

Enzo Biochem operates in the life sciences tools sector, which is currently facing headwinds such as decreased government grants and reduced R&D budgets. This broader industry trend has directly impacted Enzo's Products segment, contributing to its revenue decline. The company's strategic review and shift to OTCQX reflect a challenging market environment and a need for re-evaluation of its business model or ownership structure to enhance shareholder value.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess against global benchmarks. Therefore, a detailed comparison to industry standards is not possible based solely on the provided text.
• The revenue decline of 20% for the quarter and 18% for the nine months suggests underperformance relative to a growing or stable life sciences tools market, though specific industry growth rates are not provided for direct comparison.
• The gross profit margin decline from 47% to 39% (or 41% excluding inventory provision) indicates a deterioration in profitability that may be worse than industry averages, especially if competitors are managing fixed costs more effectively or experiencing less severe revenue contractions.

Management Changes

Legal Proceedings

• Ransomware Attack Regulatory Inquiries: Resolved with New York, Connecticut, and New Jersey Attorneys General for $4.5 million (paid September 2024). Inquiry from U.S. Department of Health and Human Services Office for Civil Rights is ongoing.
• In re Enzo Biochem Data Breach Litigation (EDNY Federal Action): Class-wide settlement agreement for $7.5 million approved on June 10, 2025. Approximately $0.8 million paid in March 2025, remaining $6.7 million due by July 10, 2025.
• Maria Sgambati et al., v. Enzo Biochem, Inc., et al. (N.Y. Sup. Ct.): Putative class action related to data incident, stayed pending EDNY Federal Action resolution. Company intends to seek dismissal.
• Louis v. Enzo Biochem, Inc. et al. (N.Y. Sup. Ct.): Putative class action related to data incident, motion to stay pending EDNY Federal Action resolution. Company intends to seek dismissal.
• Barry Weiner Employment Dispute: Settled on October 24, 2023, with a payment of $3.6 million to Mr. Weiner in November 2023.
• Elazar Rabbani (as plaintiff) v. Mary Tagliaferri, et al. (Derivative Case): Discontinued by plaintiff without prejudice on November 15, 2024.
• Connecticut Medicaid Overbilling Settlement: Finalized August 14, 2024, with payments of $1.7 million to Connecticut Medicaid and $0.175 million for whistleblower legal fees in August 2024.
• James G. Wolf et al. Appraisal Action: Petitioners seeking appraisal of shares, claiming fair value greater than $3.50 per share. Motion to compel advance payment filed April 1, 2025. Company disputes and will oppose.
• Whistleblower Complaint (SDNY): Alleging false billing of Medicaid and Medicare for COVID-19 tests. Government not intervening, but private plaintiffs pursuing. Company's motion to dismiss due June 23, 2025. Outcome not estimable.
• Elazar Rabbani Employment Termination Arbitration: Ongoing arbitration regarding termination benefits and counterclaims. Hearing scheduled for November 17-21, 2025.
• Patent Infringement Litigation (Becton Dickinson): One case pending, claims stayed. PTO issued a final rejection of claims in ex parte reexamination for the '197 patent on February 6, 2025. Company considering appeal options.

Related Party Transactions

• Settlement payment of $3.6 million to Barry Weiner, former President, in November 2023, resolving an employment dispute.
• Ongoing arbitration with Elazar Rabbani, former CEO, regarding termination benefits, following severance payments and tax payments made on his behalf in 2022.

Stakeholder Impact

• **Shareholders**: Negative impact from significant revenue decline, widening operating losses, and voluntary delisting from NYSE to OTCQX, which may reduce liquidity. Potential positive impact from the strategic review if it leads to value-maximizing transactions. A special cash dividend of $0.10 per share was paid in December 2024.
• **Customers**: Continued provision of products and services through the Enzo Life Sciences division, but the decline in revenues suggests potential impact from reduced R&D budgets and government grants in the life sciences tools sector.
• **Employees**: Impacted by cost containment measures, including lower headcount in the Products segment. Some employees' information was involved in the April 2023 ransomware attack.
• **Creditors**: The company's cash position decreased, but management believes it has sufficient funds for the next twelve months. Convertible debentures were fully repaid in May 2024, and a Swiss government loan is being amortized.
• **Regulatory Authorities**: Engaged in multiple regulatory inquiries and settlements related to the ransomware attack and past billing practices, indicating ongoing scrutiny.

Next Steps

• The Board's Strategic Committee will continue to evaluate a broad range of opportunities to maximize shareholder value, including potential strategic transactions, business combinations, a full sale of the company, or return of excess capital.
• The company will continue to defend against the pending class actions related to the April 2023 data incident, with the intention to seek dismissal of the state actions once the EDNY Federal Action settlement receives final approval.
• The company will file papers opposing the motion to compel an advance payment in the James G. Wolf et al. appraisal action in early July 2025.
• The company's motion to dismiss the whistleblower complaint in the Southern District of New York is due on June 23, 2025.
• The arbitration hearing with former CEO Elazar Rabbani is scheduled for November 17-21, 2025.
• The company is considering appeal options regarding the final rejection of claims in the ex parte reexamination proceedings for the '197 patent.

Key Dates

Recommendation

Keywords

Life Sciences, Biotechnology, Diagnostics, SEC Filing, 10-Q, Financial Results, Revenue Decline, Operating Loss, Strategic Review, NYSE Delisting, OTCQX, Ransomware Attack, Data Breach, Legal Proceedings, Patent Infringement, Cash Flow, Enzo Biochem, ENZB